SCHEMBL5537634

SCHEMBL5537634

[CH2]c1ccccc1Oc1cccc(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.49
POLB P06746 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MTNR1B P49286 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.45
NPSR1 Q6W5P4 2/20 0.45
MAPT P10636 1/20 0.45
MAPK1 P28482 2/20 0.45
ALDH1A1 P00352 5/20 0.44
ACHE P22303 1/20 0.44
HTT P42858 1/20 0.44
MAOB P27338 1/20 0.43
NFE2L2 Q16236 1/20 0.42
CYP3A4 P08684 2/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
GAA P10253 1/20 0.42
MEN1 O00255 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5540267 0.89 ALDH1A1 (0.47) POLBSMN1; SMN2L3MBTL1MAPK1ALDH1A1
SCHEMBL3092408 0.82 ALDH1A1 (0.59) POLBSMN1; SMN2L3MBTL1MAPTMAPK1
SCHEMBL13791510 0.82 MAPK1 (0.65) KDM4EPOLBSMN1; SMN2MTNR1BL3MBTL1
SCHEMBL5541683 0.81 ALDH1A1 (0.64) SMN1; SMN2L3MBTL1NPSR1ALDH1A1ACHE
SCHEMBL2089820 0.80 ALDH1A1 (0.57) L3MBTL1MAPK1ALDH1A1ACHEHTT
SCHEMBL5609585 0.79 AR (0.55) KDM4EPOLBSMN1; SMN2MTNR1BL3MBTL1
SCHEMBL5546520 0.79 CA12 (0.57) L3MBTL1MAPTMAPK1ALDH1A1HTT
SCHEMBL5537524 0.79 CA12 (0.57) L3MBTL1MAPTMAPK1ALDH1A1HTT
SCHEMBL1341320 0.78 ALDH1A1 (0.69) KDM4EPOLBSMN1; SMN2MTNR1BL3MBTL1
SCHEMBL30567118 0.78 ALDH1A1 (0.69) KDM4EPOLBSMN1; SMN2MTNR1BL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KDM4E 4854/4885POLB 1637/4885SMN1; SMN2 3985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.